TRX Gold Reports Record Throughput, Reaffirms Guidance, and Accelerates Plant Expansion – But Self-Funding Proof Remains Elusive

What happened

TRX Gold announced preliminary Q3 2026 results with record throughput, reaffirmed FY2026 production guidance of 25,000–30,000 oz, and said it is accelerating the processing plant expansion. The announcement aligns with management's narrative of strong operating momentum and self-funded growth, but the detailed financials (cash flow, capex, balance sheet) remain undisclosed in SEC filings, as the latest 6-K contained only proxy materials. The DeepValue report rates the stock a 'WAIT' at $1.59, citing a 24x EV/EBITDA and the need to verify that internal cash generation can fund Track 1 and Track 2 capex without equity dilution. While the record throughput and reaffirmed guidance are supportive, the critical proof points – sustained free cash flow positive through the upgrade cycle and on-time milestone delivery – have yet to be demonstrated. As a single-asset producer with high operating leverage, TRX's valuation already prices in successful execution, leaving little room for error if gold prices soften or costs rise above the $1,400–$1,600/oz guidance.

Implication

TRX's latest update provides near-term operational momentum but offers no new clarity on the funding gap, which the DeepValue report identifies as the controlling variable. Investors should monitor the upcoming Q3 2026 detailed results and cash flow statement to assess whether internally generated cash can cover the $15–$20M FY2026 capex without equity issuance. The acceleration of the plant expansion could pressure near-term free cash flow if procurement and construction costs rise faster than anticipated. Until two consecutive quarters show positive free cash flow during the upgrade cycle, the stock's risk-reward is skewed to the downside given its elevated multiple of 24x EV/EBITDA. A pullback toward the attractive entry price of $1.20 would provide a better margin of safety for new positions.

Thesis delta

The news of record throughput and reaffirmed guidance modestly reduces downside risk on near-term production, but the core thesis remains unchanged: the stock's valuation assumes successful self-funded expansion, which remains unproven. The acceleration of the plant expansion adds execution risk, as it may increase capex intensity before the benefits of Track 1 are realized. Therefore, the WAIT rating is maintained, with the same re-assessment windows and trigger points.